Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NRXP
- Price
- 2.03
- Stock movement down
- -0.02 (-0.98%)
- Company name
- NRX Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 24.55M
- Ent value
- 46.19M
- Price/Sales
- 1534.44
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -63.09%
- 3 year return
- -55.38%
- 5 year return
- -54.72%
- 10 year return
- -
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NRXP does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1534.44 |
| Price to Book | - |
| EV to Sales | 2886.81 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 12.09M |
| EPS (TTM) | -1.86 |
| FCF per share (TTM) | -1.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 16.00K |
| Gross profit (TTM) | 5.00K |
| Operating income (TTM) | -20.48M |
| Net income (TTM) | -20.38M |
| EPS (TTM) | -1.86 |
| EPS (1y forward) | -0.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 31.25% |
| Operating margin (TTM) | -127975.00% |
| Profit margin (TTM) | -127375.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.65M |
| Net receivables | 6.00K |
| Total current assets | 4.11M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 4.46M |
| Accounts payable | 4.87M |
| Short/Current long term debt | 6.67M |
| Total current liabilities | 20.30M |
| Total liabilities | 23.28M |
| Shareholder's equity | -18.82M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.37M |
| Capital expenditures (TTM) | 8.00K |
| Free cash flow (TTM) | -12.37M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -456.75% |
| Return on Invested Capital | 134.63% |
| Cash Return on Invested Capital | 81.71% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.05 |
| Daily high | 2.14 |
| Daily low | 2.01 |
| Daily Volume | 94K |
| All-time high | 627.10 |
| 1y analyst estimate | 31.67 |
| Beta | 1.27 |
| EPS (TTM) | -1.86 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NRXP | S&P500 | |
| Current price drop from All-time high | -99.68% | -12.04% |
| Highest price drop | -99.81% | -56.47% |
| Date of highest drop | 14 Nov 2024 | 9 Mar 2009 |
| Avg drop from high | -54.25% | -11.07% |
| Avg time to new high | 12 days | 12 days |
| Max time to new high | 1055 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
24.55M
Marketcap category
Small-cap
Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page